Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 18, 2026

Big Short Steve Eisman Favors Schwab, Cites Robinhood's Lack Of 'Margin For Error' Amid Bitcoin-Led Crypto Slide

View original at finance.yahoo.com
Big Short Steve Eisman Favors Schwab, Cites Robinhood's Lack Of 'Margin For Error' Amid Bitcoin-Led Crypto Slide Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Robinhood has no margin for error given its current trajectory and lofty valuation

    80% confidence

  • The forward PE for HOOD stood at 29.85, as compared to SCHW's 16.31 ratio

    80% confidence

  • A not insignificant portion of Robinhood's customers invest in crypto, and the crypto slump is directly impacting Robinhood's performance

    80% confidence

  • The renewed decline in crypto prices is a major factor hurting platforms like Robinhood and Coinbase

    80% confidence

  • Robinhood will not go up until at least crypto stabilizes

    80% confidence

  • Retail investors continue to buy every dip in the broader market, but this strategy may not hold for assets facing structural headwinds and competitive pressures when valuations offer little cushion

    80% confidence

  • As long as crypto prices keep going down, so will the stock price of Coinbase

    80% confidence

  • Robinhood trades at a 2026 PE multiple over 30 times, while Charles Schwab commands a significantly lower 17 times PE, creating a stark valuation disparity with no margin for error

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com